Myriad Genetics (MYD) Price & Analysis
MYD Stock Chart & Stats
- Day’s Range
- EUR 5.71 - EUR 5.92
- 52-Week Range
- EUR 2.45 - EUR 6.90
- Previous Close
- EUR 5.95
- Volume
- 0
- Average Volume (3M)
- 244
- Market Cap
- EUR 542.02M
- Enterprise Value
- EUR 636.61M
- Total Cash (Recent Filing)
- EUR 115.20M
- Total Debt (Recent Filing)
- EUR 210.50M
- Price to Earnings (P/E)
- ―
- Beta
- 0.21
- Next Earnings
- Nov 04, 2026
- EPS Estimate
- -0.18
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margins
Consistently high gross margins indicate that Myriad’s diagnostic products generate substantial value after direct testing costs. This provides a foundation for operating leverage if test volumes improve or expenses are controlled, while supporting continued investment in clinical evidence, reporting, and commercial adoption.
Portfolio-Focusing Divestiture
The planned divestiture could sharpen Myriad’s focus on the cancer care continuum while adding significant cash to the balance sheet. Concentrating resources on core oncology and hereditary testing may improve strategic coherence and create a clearer path toward revenue growth and profitability.
Proprietary Diagnostic Platform
A proprietary testing model supports recurring fee-for-service revenue from clinically ordered diagnostics across hereditary disease and oncology. Bioinformatics, interpretive reporting, and genetic counseling can reinforce physician adoption and make the platform more valuable as genomic medicine expands.
Bears Say
Persistent Operating Losses
Sustained operating and net losses show that strong product-level gross margins are currently overwhelmed by operating expenses. Until Myriad reaches durable operating profitability, it may have less flexibility to invest in growth, absorb setbacks, or convert diagnostic demand into shareholder value.
Weak Revenue Trend
Recent revenue stagnation or decline weakens the scale needed to absorb Myriad’s operating cost base and limits the benefit of its high gross margins. A sustained rebound in testing volumes, reimbursement, or portfolio productivity is needed to restore dependable top-line momentum.
Fragile Cash Generation
Positive operating cash flow is an improvement, but modest generation relative to the company’s losses and still-negative free cash flow indicate that cash conversion is not yet durable. Continued volatility could constrain investment capacity and increase reliance on balance-sheet resources during execution.
Myriad Genetics News
MYD FAQ
What was Myriad Genetics’s price range in the past 12 months?
What is Myriad Genetics’s market cap?
When is Myriad Genetics’s upcoming earnings report date?
How were Myriad Genetics’s earnings last quarter?
Is Myriad Genetics overvalued?
Does Myriad Genetics pay dividends?
What is Myriad Genetics’s EPS estimate?
How many shares outstanding does Myriad Genetics have?
What happened to Myriad Genetics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Myriad Genetics?
What is the TipRanks Smart Score and how is it calculated?
Myriad Genetics Stock Smart Score
Company Description
Myriad Genetics
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Samraat S. Raha
- Employees
- 2,700
- Website
- www.myriad.com
- Address
- 322 North 2200 West, Salt Lake City, UT, 84116, US
Myriad Genetics (MYD) Earnings & Revenues
MYD Company Deck
MYD Earnings Call
Earnings Call SentimentPositive
The call emphasized meaningful progress in core growth engines (double-digit hereditary cancer growth, robust GeneSight performance, solid gross margins and a deep product pipeline) and management reaffirmed full-year guidance and positive adjusted EBITDA expectations. Near-term pressures include a Q1 adjusted EBITDA loss, higher operating expense due to accelerated commercial hiring, and a notable prenatal revenue decline. Management is investing to drive back-half acceleration but execution (sales ramp, MRD adoption, payer reimbursement) will determine pace of recovery. On balance, the positives around market share gains, product launches and revenue guidance outweigh the short-term profitability and prenatal headwinds.
View all DE:MYD earnings summariesMYD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |